Literature DB >> 21890685

Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension.

Roxane Paulin1, Jolyane Meloche, Maria Helena Jacob, Malik Bisserier, Audrey Courboulin, Sébastien Bonnet.   

Abstract

Pulmonary arterial hypertension (PAH) is an obstructive vasculopathy characterized by enhanced pulmonary artery smooth muscle cell (PASMC) proliferation and suppressed apoptosis. This phenotype is sustained by the activation of the Src/signal transducer and activator of transcription 3 (STAT3) axis, maintained by a positive feedback loop involving miR-204 and followed by an aberrant expression/activation of its downstream targets such as Pim1 and nuclear factor of activated T-cells (NFATc2). Dehydroepiandrosterone (DHEA) is a steroid hormone shown to reverse vascular remodeling in systemic vessels. Since STAT3 has been described as modulated by DHEA, we hypothesized that DHEA reverses human pulmonary hypertension by inhibiting Src/STAT3 constitutive activation. Using PASMCs isolated from patients with PAH (n = 3), we demonstrated that DHEA decreases both Src and STAT3 activation (Western blot and nuclear translocation assay), resulting in a significant reduction of Pim1, NFATc2 expression/activation (quantitative RT-PCR and Western blot), as well as Survivin and upregulation of bone morphogenetic protein receptor 2 (BMPR2) and miR-204. Src/STAT3 axis inhibition by DHEA is associated with 1) mitochondrial membrane potential (tetramethylrhodamine methyl-ester perchlorate; n = 150; P < 0.05) depolarization increasing apoptosis by 25% (terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling; n = 150; P < 0.05); and 2) decreased intracellular Ca(2+) concentration (fluo-3 AM; n = 150; P < 0.05) and proliferation by 30% (PCNA). Finally, in vivo similarly to STAT3 inhibition DHEA improves experimental PAH (monocrotaline rats) by decreasing mean PA pressure and right ventricle hypertrophy. These effects were associated with the inhibition of Src, STAT3, Pim1, NFATc2, and Survivin and the upregulation of BMPR2 and miR-204. We demonstrated that DHEA reverses pulmonary hypertension in part by inhibiting the Src/STAT3.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890685     DOI: 10.1152/ajpheart.00654.2011

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  53 in total

Review 1.  Mechanisms and therapeutic potential of microRNAs in hypertension.

Authors:  Lijun Shi; Jingwen Liao; Bailin Liu; Fanxing Zeng; Lubo Zhang
Journal:  Drug Discov Today       Date:  2015-05-21       Impact factor: 7.851

Review 2.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

3.  Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor.

Authors:  Yun Teng; Lacey M Litchfield; Margarita M Ivanova; Russell A Prough; Barbara J Clark; Carolyn M Klinge
Journal:  Mol Cell Endocrinol       Date:  2014-05-17       Impact factor: 4.102

Review 4.  Sex differences in the pulmonary circulation: implications for pulmonary hypertension.

Authors:  Yvette N Martin; Christina M Pabelick
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-03-07       Impact factor: 4.733

5.  Insights from the Menstrual Cycle in Pulmonary Arterial Hypertension.

Authors:  Grayson L Baird; Thomas Walsh; Jason Aliotta; Melissa Allahua; Ruth Andrew; Ghada Bourjeily; Alexander S Brodsky; Nina Denver; Mark Dooner; Elizabeth O Harrington; James R Klinger; Margaret R MacLean; Christopher J Mullin; Mandy Pereira; Athena Poppas; Mary Whittenhall; Corey E Ventetuolo
Journal:  Ann Am Thorac Soc       Date:  2021-02

6.  Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension.

Authors:  Karim C El Kasmi; Steven C Pugliese; Suzette R Riddle; Jens M Poth; Aimee L Anderson; Maria G Frid; Min Li; Soni S Pullamsetti; Rajkumar Savai; Maria A Nagel; Mehdi A Fini; Brian B Graham; Rubin M Tuder; Jacob E Friedman; Holger K Eltzschig; Ronald J Sokol; Kurt R Stenmark
Journal:  J Immunol       Date:  2014-06-13       Impact factor: 5.422

7.  Nur77 suppresses pulmonary artery smooth muscle cell proliferation through inhibition of the STAT3/Pim-1/NFAT pathway.

Authors:  Yan Liu; Jian Zhang; Bing Yi; Ming Chen; Jia Qi; You Yin; Xiaotong Lu; Jean-Francois Jasmin; Jianxin Sun
Journal:  Am J Respir Cell Mol Biol       Date:  2014-02       Impact factor: 6.914

Review 8.  Cellular Metabolism in Lung Health and Disease.

Authors:  Gang Liu; Ross Summer
Journal:  Annu Rev Physiol       Date:  2018-11-28       Impact factor: 19.318

Review 9.  Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease.

Authors:  Peter A Hecker; Jane A Leopold; Sachin A Gupte; Fabio A Recchia; William C Stanley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-12-15       Impact factor: 4.733

10.  Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men.

Authors:  Corey E Ventetuolo; Grayson L Baird; R Graham Barr; David A Bluemke; Jason S Fritz; Nicholas S Hill; James R Klinger; Joao A C Lima; Pamela Ouyang; Harold I Palevsky; Amy J Palmisciano; Ipsita Krishnan; Diane Pinder; Ioana R Preston; Kari E Roberts; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2016-05-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.